MX2022009776A - Tratamiento de la colangitis biliar primaria con elafibranor. - Google Patents
Tratamiento de la colangitis biliar primaria con elafibranor.Info
- Publication number
- MX2022009776A MX2022009776A MX2022009776A MX2022009776A MX2022009776A MX 2022009776 A MX2022009776 A MX 2022009776A MX 2022009776 A MX2022009776 A MX 2022009776A MX 2022009776 A MX2022009776 A MX 2022009776A MX 2022009776 A MX2022009776 A MX 2022009776A
- Authority
- MX
- Mexico
- Prior art keywords
- elafibranor
- primary biliary
- treatment
- biliary cholangitis
- gft1007
- Prior art date
Links
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 title abstract 4
- 208000012654 Primary biliary cholangitis Diseases 0.000 title abstract 4
- 229950001279 elafibranor Drugs 0.000 title abstract 3
- AFLFKFHDSCQHOL-IZZDOVSWSA-N gft505 Chemical compound C1=CC(SC)=CC=C1C(=O)\C=C\C1=CC(C)=C(OC(C)(C)C(O)=O)C(C)=C1 AFLFKFHDSCQHOL-IZZDOVSWSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a una composición farmacéutica que comprende elafibranor, GFT1007 o una sal farmacéuticamente aceptable de elafibranor o de GFT1007, para su uso en el tratamiento de la colangitis biliar primaria (PBC) sin provocar y/o empeorar al menos un evento adverso asociado a la PBC.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305124 | 2020-02-10 | ||
| PCT/EP2021/052710 WO2021160519A1 (en) | 2020-02-10 | 2021-02-04 | Treatment of primary biliary cholangitis with elafibranor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009776A true MX2022009776A (es) | 2022-09-09 |
Family
ID=69784363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009776A MX2022009776A (es) | 2020-02-10 | 2021-02-04 | Tratamiento de la colangitis biliar primaria con elafibranor. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230052189A1 (es) |
| EP (1) | EP4103166A1 (es) |
| JP (1) | JP2023513670A (es) |
| KR (1) | KR20220140762A (es) |
| CN (1) | CN114980876A (es) |
| AU (1) | AU2021220519A1 (es) |
| BR (1) | BR112022015800A2 (es) |
| CA (1) | CA3163375A1 (es) |
| IL (1) | IL294502A (es) |
| MX (1) | MX2022009776A (es) |
| TW (1) | TW202143953A (es) |
| WO (1) | WO2021160519A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024184365A1 (en) * | 2023-03-06 | 2024-09-12 | Genfit | Solid dosage forms of elafibranor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2902789A1 (fr) | 2006-06-21 | 2007-12-28 | Genfit Sa | Derives de 1,3-diphenylpropane substitues, preparations et utilisations |
| AU2017242819B2 (en) * | 2016-03-31 | 2022-06-30 | Genfit | Methods of treatment of cholestatic diseases |
| CA3053418A1 (en) * | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| US20190105291A1 (en) * | 2017-09-26 | 2019-04-11 | Cymabay Therapeutics, Inc. | Treatment of cholestatic pruritus |
-
2021
- 2021-02-04 WO PCT/EP2021/052710 patent/WO2021160519A1/en unknown
- 2021-02-04 MX MX2022009776A patent/MX2022009776A/es unknown
- 2021-02-04 CN CN202180009966.XA patent/CN114980876A/zh active Pending
- 2021-02-04 CA CA3163375A patent/CA3163375A1/en active Pending
- 2021-02-04 AU AU2021220519A patent/AU2021220519A1/en active Pending
- 2021-02-04 KR KR1020227030005A patent/KR20220140762A/ko unknown
- 2021-02-04 EP EP21703686.2A patent/EP4103166A1/en active Pending
- 2021-02-04 US US17/792,217 patent/US20230052189A1/en active Pending
- 2021-02-04 BR BR112022015800A patent/BR112022015800A2/pt unknown
- 2021-02-04 IL IL294502A patent/IL294502A/en unknown
- 2021-02-04 JP JP2022546094A patent/JP2023513670A/ja active Pending
- 2021-02-08 TW TW110104824A patent/TW202143953A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023513670A (ja) | 2023-04-03 |
| US20230052189A1 (en) | 2023-02-16 |
| CA3163375A1 (en) | 2021-08-19 |
| AU2021220519A1 (en) | 2022-09-22 |
| EP4103166A1 (en) | 2022-12-21 |
| CN114980876A (zh) | 2022-08-30 |
| WO2021160519A1 (en) | 2021-08-19 |
| BR112022015800A2 (pt) | 2022-10-11 |
| IL294502A (en) | 2022-09-01 |
| KR20220140762A (ko) | 2022-10-18 |
| TW202143953A (zh) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019009443A (es) | Metodos para tratar la influenza. | |
| MX2019006721A (es) | Tratamiento para la colangitis biliar primaria. | |
| MX2019012884A (es) | Terapia de combinacion. | |
| CR20190531A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| UA105556C2 (uk) | Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами | |
| PH12019502559A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| MX2019011608A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| MX2021006884A (es) | Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina. | |
| MX2010002735A (es) | Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno. | |
| MX2022002196A (es) | Composición de liberación retardada de niclosamida y uso antiviral de la misma. | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
| MX2022009197A (es) | Metodos de tratamiento para deficiencia de alfa-1 antitripsina. | |
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| GEP20247644B (en) | Inhibitors of adrenoreceptor adrac2 | |
| TW200719903A (en) | Compositions for the treatment of neoplasms | |
| MX2022009776A (es) | Tratamiento de la colangitis biliar primaria con elafibranor. | |
| BR112022012283A2 (pt) | Combinações | |
| BR112022017998A2 (pt) | Formulações de liberação controlada compreendendo drotaverina ou sal da mesma | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2022001647A (es) | Terapia de combinacion con vildagliptina y metformina. | |
| CA3199014A1 (en) | Combination therapy for the treatment of a liver disease | |
| MX349767B (es) | Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular. | |
| MX2023002159A (es) | Composiciones y metodos para el tratamiento de la colangitis biliar primaria. | |
| BR112018008835A8 (pt) | composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla |